Back to top

gene-editing: Archive

Zacks Equity Research

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

CRMDNegative Net Change EDITNegative Net Change KNSANegative Net Change PHARNegative Net Change